Perspective Therapeutics (CATX) Stock
Small healthcare company advancing early stage drug pipelines. Here's the price, business snapshot, and what's worth knowing about Perspective Therapeutics in October 2026.
Perspective Therapeutics Inc (ticker: CATX) is a small-cap healthcare company with a market capitalisation of about $230.96M. Investors should know this stock may be driven by company-specific factors such as clinical progress, regulatory milestones, licensing deals and funding rounds rather than steady revenue streams. Small-cap healthcare firms can offer significant upside if trials or partnerships succeed, but they also carry higher volatility, execution and regulatory risk. Important considerations include the company’s cash runway, debt position, management experience, and any reported pipeline or intellectual property updates. Public filings, investor presentations and regulator announcements are key sources for timely information. Given the speculative nature of many early-stage healthcare firms, this stock may suit investors comfortable with higher risk and a long investment horizon. This is general educational information and not personalised investment advice; returns are not guaranteed and the value of investments can fall as well as rise.
Perspective Therapeutics (CATX) Stock Forecast
Analyst price target, next 12 months
$13.12
+966.5% vs today's $1.23
Price range over the last 12 months
Close to its 12-month low
Analysts covering Perspective Therapeutics have a consensus 12-month target of $13.12, above the current price of $1.23.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 27 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Perspective Therapeutics stock with a target price of $13.12, indicating strong growth potential.
Financial Health
Perspective Therapeutics is generating low revenue and cash flow, indicating financial challenges.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Catalysts to Watch
Clinical readouts, regulatory announcements and partnership deals can move the stock; such events may create opportunity but also add volatility.
Funding & Runway
Cash position and access to financing are crucial for early-stage healthcare firms; dilution is possible if new capital is required.
Research Sources
Use filings, investor presentations and regulator sites for verified updates; third-party commentary can help but check primary documents.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
